Pseudomonas Response To Hyperbaric Oxygen Therapy
Hand-Foot Syndrome From 5-FU, Doxorubicin, Docetaxel And Capecitabine
An adverse reaction from 5-FU, Doxorubicin, docetaxel and Capecitabine chemotherapy has been termed the hand-foot syndrome (HFS) and is also called palmar plantar erythrodysesthesia (PPE). HFS/PPE is a frequent toxic reaction which causes a painful erythrma, often preceeded by paresthesia in the palm of the hands and sole of the feet. Histology shows mild spongiosis, scattered necrotic dyskeratotic keratinocytes and vascular degeneration of the basal layer of the skin. Dermal changes include dilated blood vessels, papillary edema and pervascular lymphohistiocytic infiltrate. In some severe cases there has been loss of hands and feet. Treatment has been drug withdrawal and supportive topical wound care. Based on psysiological effects of HBOT, which are vasoconstriction, edema reduction, stimulation of capillary formation and increased oxygenation, the use of HBOT might significantly decreases the morbidity of HFS/PPE syndrome caused by 5-FU, Doxorubicin, docetaxal and Capecitabine.
Disclaimer
The ideas and advice contained on these Web pages are not intended to be a substitute for a careful medical evaluation and treatment by a competent, licensed personal health care professional. Dr. Spiegel does not recommend changing any current medications or adding any new therapies without personally consulting a fully qualified physician.
Varying and even conflicting views are held by other segments of the medical profession. The information presented on these Web pages is intended to be educational in nature and is not intended as a basis for diagnosis or treatment.
Printed with Permission
